Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study

Vitale, Alessandro; Burra, Patrizia; Frigo, Anna Chiara; Trevisani, Franco; Farinati, Fabio; Spolverato, Gaya; Volk, Michael L.; Giannini, Edoardo G.; Ciccarese, Francesca; Piscaglia, Fabio; Rapaccini, Gian Lodovico; Marco, Mariella Di; Caturelli, Eugenio; Zoli, Marco; Borzio, Franco; Cabibbo, Giuseppe; Felder, Martina; Gasbarrini, Antonio; Sacco, Rodolfo; Foschi, Francesco Giuseppe; Missale, Gabriele; Morisco, Filomena; Svegliati‐Baroni, Gianluca; Virdone, Roberto; Cillo, Umberto

doi:10.1016/j.jhep.2014.10.037

Cited by 197 publications

(213 citation statements)

References 25 publications

Supporting

Mentioning

187

Contrasting

Unclassified

Order By: Relevance

“…Запущенные случаи ГЦР представляют собой различный спектр ситуаций, но все отнесены к стадии С по класси-фикации BCLC, которая, в частности, включает в себя: 1) отдаленные метастазы; 2) местно-распространенную опухоль с портальным тромбозом; 3) узловые или инфильтративные опухоли, связанные с Child-Pugh A или B и т. д. Стадия С также связана только с одной опцией ле-чения (сорафениб) [26]. Расширение показаний для хирургического лечения ГЦР нуждается в активном изучении [28,29,30]. В некоторых неоперабельных случаях ГЦР может быть эффективной хемоэмболизацией [31,32].…”

Section: обзор исторического развития шкал и классификаций при гцкunclassified

The problem of current classications of the hepatocellular carcinoma. Analytical review

Ротин¹,

Мороз²

2017

Zlokač. opuholi

View full text Add to dashboard Cite

Section: обзор исторического развития шкал и классификаций при гцкunclassified

The problem of current classications of the hepatocellular carcinoma. Analytical review

Ротин¹,

Мороз²

2017

Zlokač. opuholi

View full text Add to dashboard Cite

“…These patients deserve priority in the transplantation selection process [25]. Namely, patients with decompensated cirrhosis (BCLC stage D), successful down-staging, or with a recurrence or a partial response to a non-transplant therapy all have an intrinsically high transplant benefit due to their poor long-term expected survival without…”

Section: The Transplant Benefit As An Endpointmentioning

confidence: 99%

Surgery and Hepatocellular Carcinoma

et al. 2016

Self Cite

View full text Add to dashboard Cite

The optimal surgical strategy for hepatocellular carcinoma (HCC) is under active debate. Bio-markers of the liver functional reserve as well as volumetric analysis of the future liver remnant are essential for safe liver resection of HCC. The present algorithms applied to surgical strategies for HCC are not ideal because many patients who could potentially undergo safe resection are deemed liver transplant candidates in Western countries, whereas the opposite is the case in Eastern countries. In addition, there is too much focus on expanded criteria for patients with HCC to undergo liver transplantation. The transplantation benefit for patients with HCC should be considered based not only on the individual's benefit, but also on the effect of other patients waiting for LT for other indications.

show abstract

“…However, patients with intermediate HCC vary widely in tumor size, tumor volume, overall health, and other factors, and so derive different benefit from TACE. In recent years, many studies have validated the BCLC treatment recommendation [7,[18][19][20][21][22][23] . Liver resection has been widely performed in patients with intermediate HCC, and many investigators have argued that liver resection is as safe as TACE for intermediate HCC and provides better survival outcomes in selected patients [24][25][26][27][28][29][30][31] .…”

Section: Liver Resection Vs Tace For Intermediate Hccmentioning

confidence: 99%